DNLI vs GANX

Denali's 10x growth potential has significantly diminished due to critical setbacks since the last analysis. The Phase 2 DNL343 (ALS) trial's failure on March 22, 2026, directly contradicts previous assumptions of 'on-track' pipeline progression, deeply impacting competitive positioning and overall confidence. This is compounded by a Q4 2025 earnings miss, a cut in 2026 R&D guidance, and concernin...

Gain Therapeutics continues to offer high-risk, high-reward potential. The core investment thesis is strengthened by recent positive Phase 1b clinical data for GT-02287, demonstrating an 81% average CSF GluSph decrease, and a clear path to FDA IND clearance in 2Q26 and Phase 2 initiation in 3Q26. This de-risks a major catalyst identified in the previous analysis. Furthermore, the company reported ...